Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies

Prenatal Diagnosis

Volumn 30, Issue 3, 2010, Pages 212-215

  Sifakis, Stavros ^a   Akolekar, Ranjit ^b   Syngelaki, Argyro ^b,c   De Cruz, Jader ^b,c   Nicolaides, Kypros H ^b,c  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

First trimester screening; Human placental growth hormone; Nuchal translucency; Pregnancy associated plasma protein A; Trisomy 18; Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; GROWTH HORMONE; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; FEMALE; FETUS; GESTATION PERIOD; GROWTH HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRIORITY JOURNAL; TRISOMY 18; TRISOMY 21;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; FEMALE; HUMANS; NECK; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; TRISOMY;

EID: 77349100810     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2438     Document Type: Article

References (20)

1. Alsat E, Guibourdenche J, Couturier A, Evain-Brion D. 1998. Physiological role of human placental growth hormone. Mol Cell Endocrinol 140: 121-127.
2. Baviera G, Carbone C, Corrado F, Mastrantonio P. 2004. Placental growth hormone in Down's syndrome screening. J Matern Fetal Neonatal Med 16: 241-243.
3. Brizot M, Jauniaux E, Mckie A, Farzaneh F, Nicolaides K. 1995. Placental expression of alpha and beta subunits of human chorionic gonadotrophin in early pregnancies with Down's syndrome. Hum Reprod 10: 2506-2509.
4. Chellakooty M, Vangsgaard K, Larsen T,et al. 2004. A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. J Clin Endocrinol Metab 89: 384-391.
5. Christiansen M, Larsen SO, Oxvig C, et al. 2004. Screening for Down's syndrome in early and late first and second trimester using six maternal serum markers. Clin Genet 65: 11-16.
6. Donalson K, Turner S, Wastell H, Cuckle H. 2008. Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies. Prenat Diagn 28: 904-907.
7. Frankenne F, Closset J, Gomez F, Scippo ML, Smal J, Hennen G. 1988. The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 66: 1171-1180.
8. Frendo JL, Vidaud M, Guibourdenche J, et al. 2000. Defect of villous cytotrophoblast differentiation into syncytiotrophoblast in Down's syndrome. J Clin Endocrinol Metab 85: 3700-3707.
9. Fuglsang J, Ovesen P. 2006. Aspects of placental growth hormone physiology. Growth Horm IGF Res 16: 67-85.
10. Igout A, Scippo ML, Frankenne F, Hennen G. 1988. Cloning and nucleotide sequence of placental hGH-V cDNA. Arch Int Physiol Biochim 96: 63-67.
11. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. 2008a. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 31: 618-624.
12. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. 2008b. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493-502.
13. Lacroix MC, Guibourdenche J, Fournier T, et al. 2005. Stimulation of human trophoblast invasion by placental growth hormone. Endocrinology 146: 2434-2444.
14. Moghadam S, Engel W, Bougoussa M, Hennen G, Igout A, Sancken U. 1998. Maternal serum placental growth hormone and insulinlike growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: implications for prenatal diagnosis of trisomy 21. Fetal Diagn Ther 13: 291-297.
15. Papadopoulou E, Sifakis S, Giahnakis E, et al. 2008. Human placental growth hormone is increased in maternal serum in pregnancies affected by Down syndrome. Fetal Diagn Ther 23: 211-216.
16. Scippo ML, Frankenne F, Hooghe-Peters EL, Igout A, Velkeniers B, Hennen G. 1993. Syncytiotrophoblastic localization of the human growth hormone variant mRNA in the placenta. Mol Cell Endocrinol 92: R7-R13.
17. Sifakis S, Papadopoulou E, Konstantinidou A, et al. 2009. Increased levels of human placental growth hormone in the amniotic fluid of pregnancies affected by Down syndrome. Growth Horm IGF Res 19: 121-125.
18. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343-346.
19. Spencer K, Cowans NJ, Uldbjerg N, Vereecken A, TØrring N. 2008. First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised? Prenat Diagn 28: 1156-1159.
20. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. 2008. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 31: 376-383.